CA2176848A1 - Utilisation de la pentoxyfylline dans le traitement de la sclerose en plaques - Google Patents

Utilisation de la pentoxyfylline dans le traitement de la sclerose en plaques

Info

Publication number
CA2176848A1
CA2176848A1 CA002176848A CA2176848A CA2176848A1 CA 2176848 A1 CA2176848 A1 CA 2176848A1 CA 002176848 A CA002176848 A CA 002176848A CA 2176848 A CA2176848 A CA 2176848A CA 2176848 A1 CA2176848 A1 CA 2176848A1
Authority
CA
Canada
Prior art keywords
day
patient
dosage
therapy
pentoxyphylline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002176848A
Other languages
English (en)
Inventor
Peter Rieckmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DR RENTSCHLER & Co MEDIZIN KG GmbH
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2176848A1 publication Critical patent/CA2176848A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne l'utilisation de la pentoxyfylline dans le traitement de la sclérose en plaques évoluant par poussées successives ou progressivement de manière chronique. Cette substance peut s'utiliser seule ou en combinaison avec des corticostéroïdes, à raison de 0,01 à 6,0 g/jour, indépendamment de l'éventuelle présence de corticostéroïdes.
CA002176848A 1993-12-16 1994-12-16 Utilisation de la pentoxyfylline dans le traitement de la sclerose en plaques Abandoned CA2176848A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DEP4343034.1 1993-12-16
DE4343034A DE4343034C1 (de) 1993-12-16 1993-12-16 Verwendung von Pentoxifyllin zur Behandlung von Multipler Sklerose

Publications (1)

Publication Number Publication Date
CA2176848A1 true CA2176848A1 (fr) 1995-06-22

Family

ID=6505251

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002176848A Abandoned CA2176848A1 (fr) 1993-12-16 1994-12-16 Utilisation de la pentoxyfylline dans le traitement de la sclerose en plaques

Country Status (10)

Country Link
EP (1) EP0734262A1 (fr)
JP (1) JPH09506603A (fr)
CA (1) CA2176848A1 (fr)
CZ (1) CZ170896A3 (fr)
DE (1) DE4343034C1 (fr)
FI (1) FI962473A (fr)
NO (1) NO962503L (fr)
PL (1) PL314588A1 (fr)
SK (1) SK76696A3 (fr)
WO (1) WO1995016450A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19544768C1 (de) * 1995-11-30 1997-07-10 Rentschler Arzneimittel Verwendung einer Kombination aus Pentoxifyllin mit Typ-I-Interferonen zur Behandlung der Multiplen Sklerose
US6294350B1 (en) * 1997-06-05 2001-09-25 Dalhousie University Methods for treating fibroproliferative diseases
AU2001262252A1 (en) * 2000-05-15 2001-11-26 Bayer Aktiengesellschaft Means for treating attacks of auto-immune diseases
US20070105878A1 (en) * 2005-10-03 2007-05-10 Andrew Reaume Purine formulations and methods for managing disorders
CN109364250A (zh) * 2012-10-09 2019-02-22 比奥根Ma公司 联合治疗及用于治疗脱髓鞘病症的用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4307883A1 (en) * 1992-03-12 1993-09-23 Westarp Martin Egon Dr Med Use of anti-retroviral substances - to treat motor-neuronal diseases
US5763446A (en) * 1992-03-26 1998-06-09 University Of Southern California Use of pentoxifylline and other tumor necrosis factor blockers for the treatment of aids-associated optic neuropathy and other central nervous system diseases

Also Published As

Publication number Publication date
JPH09506603A (ja) 1997-06-30
WO1995016450A1 (fr) 1995-06-22
NO962503D0 (no) 1996-06-13
PL314588A1 (en) 1996-09-16
FI962473A (fi) 1996-07-16
DE4343034C1 (de) 1995-06-08
NO962503L (no) 1996-06-13
EP0734262A1 (fr) 1996-10-02
SK76696A3 (en) 1997-04-09
FI962473A0 (fi) 1996-06-14
CZ170896A3 (en) 1997-01-15

Similar Documents

Publication Publication Date Title
EP1296671B1 (fr) Analogues de gabapentine pour traiter les troubles du sommeil
US5817699A (en) Process for the preparation of ketamine ointment
JPH06508836A (ja) 光学的に純粋なｒ（＋）オンダンセトロンを使用する嘔吐、吐き気および他の障害の治療のための方法および組成物
KR101900520B1 (ko) 복합 조성물
US4221784A (en) Process and composition for treating disorders by administering lecithin
RU2210360C1 (ru) Психотропное средство
US5248678A (en) Methods for increasing arousal and alertness and for the amelioration of comatose states
CA2176848A1 (fr) Utilisation de la pentoxyfylline dans le traitement de la sclerose en plaques
US5260289A (en) Composition for treating pain, method for treating pain and composition for reinforcing pain relief action
JPS5942649B2 (ja) 重症筋無力症治療剤
US4954486A (en) Furosemide as tinnitus suppressant
JPH08512311A (ja) 慢性疲労症候群治療用ヒ素医薬
US9433608B2 (en) Compositions and method for treatment of ischemic neuronal reperfusion injury
CN109172550B (zh) 一种复合麻醉药物
EP0575841B1 (fr) Composition contenant le hydrochlorure de dibucaine, un salicylate, le bromure de calcium et un stéroid antiphlogistique pour le traitement de la douleur
DE3780157T2 (de) Verwendung von 4-butyl-1,2-diphenyl-pyrazolidin-3,5-dion als antivirales arzneimittel gegen aids.
KR960014873B1 (ko) 제피론을 함유하는 공황(恐慌)장애 경감용 약학 조성물
EP0626849A1 (fr) Utilisation de la brofaromine comme agent de traitement du stress post-traumatique
US4731380A (en) Tolerstat as an agent for diabetic periodontitis
EP0256629A2 (fr) Tolrestat ou l'un de ses sels comme médicament immunostimulant
JPH0317016A (ja) 神経系症状の処置剤
STONE SUBARACHNOID ADMINISTRATION OF PYRIDOXINE HYDRO-CHLORIDE IN DISEASES OF THE NERVOUS SYSTEM:(PRELIMINARY REPORT)
US3714359A (en) Compositions with adrenolytic action for use in therapy
US4716177A (en) Tolrestat for inhibition of weight gain
DupuY et al. Dihydrogenated ergot alkaloids in the treatment of essential hypertension

Legal Events

Date Code Title Description
FZDE Discontinued